Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 2/20 | 0.41 |
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CA7 | P43166 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.41 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | PDE1A | P54750 | 1/20 | 0.40 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31644242 | 1.00 | SMN1; SMN2 (0.52) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL24773784 | 0.91 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL2129042 | 0.85 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL1085394 | 0.84 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL25246581 | 0.81 | SMN1; SMN2 (0.47) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL1430698 | 0.80 | ALDH1A1 (0.58) | SMN1; SMN2KDM4EALDH1A1CYP3A4MAPT | |
| SCHEMBL15525056 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL2129432 | 0.78 | NR1H2 (0.47) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL17076373 | 0.78 | NR1H2 (0.47) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 | |
| SCHEMBL2129072 | 0.78 | SMN1; SMN2 (0.44) | SMN1; SMN2KDM4EALDH1A1CYP3A4TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | HEPAGENE THERAPEUTICS HK LTD (CN) | 2024-03-21 | — | — | US | disclosed |
| CN-116490505-A | MNK inhibitors | 和博医药有限公司 | 2023-07-25 | — | — | CN | disclosed |
| EP-4200296-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (HK) | 2023-06-28 | — | — | EP | disclosed |
| WO-2022038563-A1 | MNK INHIBITORS | Hepagene Therapeutics (HK) Limited (CN) | 2022-02-24 | — | — | WO | disclosed |
| EP-3808739-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2021-04-21 | — | — | EP | disclosed |
| EP-3309152-B1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMA (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3412668-B1 | A SELECTIVE INHIBITOR OF PHOSPHATIDYLINOSITOL 3-KINASE-GAMMA | VERTEX PHARMA (US) | 2020-02-05 | — | — | EP | disclosed |
| US-10301304-B2 | Selective inhibitor of phosphatidylinositol 3-kinase-gamma | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-28 | — | — | US | disclosed |
| US-10301304-B2 | Selective inhibitor of phosphatidylinositol 3-kinase-gamma | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2019-05-28 | — | — | US | disclosed |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | EFFECTOR THERAPEUTICS, INC. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-2516417-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2012-10-31 | — | — | EP | disclosed |
| CN-102762548-A | Isoindolinone inhibitors of phosphatidylinositol 3-kinase | VERTEX PHARMA | 2012-10-31 | — | — | CN | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-09 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-02-16 | — | — | US | disclosed |
| WO-2011087776-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
| WO-2011087776-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092799-A1 | MNK INHIBITORS | MKNK1, MATK, NEK1 | SMN1; SMN2 360/4885KDM4E 777/4885ALDH1A1 4526/4885 |
| US-20120040950-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | SMN1; SMN2 1801/4885KDM4E 2889/4885ALDH1A1 3381/4885 |
| US-20190152988-A1 | ISOINDOLINE, AZAISOINDOLINE, DIHYDROINDENONE AND DIHYDROAZAINDENONE INHIBITORS OF MNK1 AND MNK2 | NEK9, NEK2, NEK3 | SMN1; SMN2 723/4885KDM4E 2745/4885ALDH1A1 2954/4885 |
| US-20120202784-A1 | ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | PIK3CD, PIK3CA, PIK3R5 | SMN1; SMN2 1801/4885KDM4E 2889/4885ALDH1A1 3381/4885 |
| US-10301304-B2 | Selective inhibitor of phosphatidylinositol 3-kinase-gamma | PIK3CA, PIK3CG, PIK3CD | SMN1; SMN2 1669/4885KDM4E 1682/4885ALDH1A1 4417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.